These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 36194178)

  • 1. Organoids from patient biopsy samples can predict the response of BC patients to neoadjuvant chemotherapy.
    Shu D; Shen M; Li K; Han X; Li H; Tan Z; Wang Y; Peng Y; Tang Z; Qu C; Jin A; Liu S
    Ann Med; 2022 Dec; 54(1):2581-2597. PubMed ID: 36194178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-Derived Organoids from Locally Advanced Gastric Adenocarcinomas Can Predict Resistance to Neoadjuvant Chemotherapy.
    Yoon C; Lu J; Kim BJ; Cho SJ; Kim JH; Moy RH; Ryeom SW; Yoon SS
    J Gastrointest Surg; 2023 Apr; 27(4):666-676. PubMed ID: 36627466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer.
    Yao Y; Xu X; Yang L; Zhu J; Wan J; Shen L; Xia F; Fu G; Deng Y; Pan M; Guo Q; Gao X; Li Y; Rao X; Zhou Y; Liang L; Wang Y; Zhang J; Zhang H; Li G; Zhang L; Peng J; Cai S; Hu C; Gao J; Clevers H; Zhang Z; Hua G
    Cell Stem Cell; 2020 Jan; 26(1):17-26.e6. PubMed ID: 31761724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreatic Cancer Patient-derived Organoids Can Predict Response to Neoadjuvant Chemotherapy.
    Demyan L; Habowski AN; Plenker D; King DA; Standring OJ; Tsang C; St Surin L; Rishi A; Crawford JM; Boyd J; Pasha SA; Patel H; Galluzzo Z; Metz C; Gregersen PK; Fox S; Valente C; Abadali S; Matadial-Ragoo S; DePeralta DK; Deutsch GB; Herman JM; Talamini MA; Tuveson DA; Weiss MJ
    Ann Surg; 2022 Sep; 276(3):450-462. PubMed ID: 35972511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
    Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L; Eiermann W; Semiglazov V; Lluch A; Tjulandin S; Zambetti M; Moliterni A; Vazquez F; Byakhov MJ; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Magazzù D; Heinzmann D; Steinseifer J; Valagussa P; Baselga J
    Lancet Oncol; 2014 May; 15(6):640-7. PubMed ID: 24657003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients.
    Wu H; Wang W; Zhang Y; Chen Y; Shan C; Li J; Jia Y; Li C; Du C; Cai Y; Zhang Y; Zhang S; Wu F
    Int J Cancer; 2024 Jul; 155(2):324-338. PubMed ID: 38533706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity.
    Sachs N; de Ligt J; Kopper O; Gogola E; Bounova G; Weeber F; Balgobind AV; Wind K; Gracanin A; Begthel H; Korving J; van Boxtel R; Duarte AA; Lelieveld D; van Hoeck A; Ernst RF; Blokzijl F; Nijman IJ; Hoogstraat M; van de Ven M; Egan DA; Zinzalla V; Moll J; Boj SF; Voest EE; Wessels L; van Diest PJ; Rottenberg S; Vries RGJ; Cuppen E; Clevers H
    Cell; 2018 Jan; 172(1-2):373-386.e10. PubMed ID: 29224780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
    Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
    World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
    Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
    Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-Derived Organoids Can Guide Personalized-Therapies for Patients with Advanced Breast Cancer.
    Chen P; Zhang X; Ding R; Yang L; Lyu X; Zeng J; Lei JH; Wang L; Bi J; Shao N; Shu D; Wu B; Wu J; Yang Z; Wang H; Wang B; Xiong K; Lu Y; Fu S; Choi TK; Lon NW; Zhang A; Tang D; Quan Y; Meng Y; Miao K; Sun H; Zhao M; Bao J; Zhang L; Xu X; Shi Y; Lin Y; Deng C
    Adv Sci (Weinh); 2021 Nov; 8(22):e2101176. PubMed ID: 34605222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
    Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
    Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.
    Bertucci F; Fekih M; Autret A; Petit T; Dalenc F; Levy C; Romieu G; Bonneterre J; Ferrero JM; Kerbrat P; Soulie P; Mouret-Reynier MA; Bachelot T; Lerebours F; Eymard JC; Deblock M; Lortholary A; Hardy-Bessard AC; Barthelemy P; Bonnefoi H; Charafe-Jauffret E; Bidard FC; Viens P; Lemonnier J; Pierga JY
    Lancet Oncol; 2016 May; 17(5):600-11. PubMed ID: 27032301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
    von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
    Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer organoids from malignant pleural effusion-derived tumor cells as an individualized medicine platform.
    Pan B; Zhao D; Liu Y; Li N; Song C; Li N; Li X; Zhao Z
    In Vitro Cell Dev Biol Anim; 2021 May; 57(5):510-518. PubMed ID: 33950403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.
    Giacchetti S; Hamy AS; Delaloge S; Brain E; Berger F; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Saghatchian M; Lerebours F; Mazouni C; Tembo O; Espié M; Reyal F; Marty M; Asselain B; Pierga JY
    Eur J Cancer; 2017 Apr; 75():323-332. PubMed ID: 28279941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer.
    Jin X; Jiang YZ; Chen S; Yu KD; Ma D; Sun W; Shao ZM; Di GH
    BMC Cancer; 2016 Aug; 16():606. PubMed ID: 27495967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
    Nitz U; Gluz O; Graeser M; Christgen M; Kuemmel S; Grischke EM; Braun M; Augustin D; Potenberg J; Krauss K; Schumacher C; Forstbauer H; Reimer T; Stefek A; Fischer HH; Pelz E; Zu Eulenburg C; Kates R; Wuerstlein R; Kreipe HH; Harbeck N;
    Lancet Oncol; 2022 May; 23(5):625-635. PubMed ID: 35405088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer.
    Divoux J; Florent R; Jacobs M; Lequesne J; Grellard JM; San C; Grossi S; Kerdja K; Clarisse B; Boudier G; Cherifi F; Briand M; Dolivet E; Johnson A; Dubois B; Harter V; Lacroix J; Raboutet C; Marie B; Rousseau N; Blanc-Fournier C; Vaur D; Figeac M; Poulain L; Weiswald LB; Emile G
    BMC Cancer; 2023 Sep; 23(1):883. PubMed ID: 37726786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
    Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
    Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.